Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026
Company

Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal

Fineline Cube Jun 28, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from...

Company Deals

ImmuneOnco Biopharmaceuticals Files for HKSE IPO with Comprehensive Tumor Immunotherapy Pipeline

Fineline Cube Jun 28, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study

Fineline Cube Jun 28, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate...

Company Drug

Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials

Fineline Cube Jun 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...

Drug

Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator

Fineline Cube Jun 28, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...

Company Medical Device

Joysbio Develops Rapid Test for SARS-CoV-2 Omicron Subvariants BA.4 and BA.5

Fineline Cube Jun 28, 2022

China-based Joysbio (Tianjin) Biotechnology Co., Ltd. has developed a rapid test to diagnose the latest...

Company Deals

Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma

Fineline Cube Jun 28, 2022

China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....

Policy / Regulatory

7th National VBP Round Venue Moved to Nanjing from Shanghai

Fineline Cube Jun 27, 2022

In a departure from previous practice, the 7th national volume-based procurement (VBP) round will not...

Company Drug

Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment

Fineline Cube Jun 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022

Fineline Cube Jun 27, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...

Company Drug

Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial

Fineline Cube Jun 27, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...

Company Deals

Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services

Fineline Cube Jun 27, 2022

China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm...

Medical Device

NMPA Approves Senscure’s Cryoablation Catheter and Kangduo’s Laparoscopic Surgery System

Fineline Cube Jun 27, 2022

The National Medical Products Administration (NMPA) has approved two innovative medical devices in China: Ningbo...

Company Deals

Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline

Fineline Cube Jun 27, 2022

Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100...

Company Deals

PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform

Fineline Cube Jun 27, 2022

Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions”...

Company Drug

GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis

Fineline Cube Jun 27, 2022

UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...

Company Deals

Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies

Fineline Cube Jun 27, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot...

Drug

Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review

Fineline Cube Jun 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...

Company Deals

Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development

Fineline Cube Jun 24, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...

Company Drug

Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China

Fineline Cube Jun 24, 2022

The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co.,...

Posts pagination

1 … 654 655 656 … 662

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.